GSK plc (GSK)
| Market Cap | 81.98B |
| Revenue (ttm) | 43.06B |
| Net Income (ttm) | 5.56B |
| Shares Out | 2.03B |
| EPS (ttm) | 2.76 |
| PE Ratio | 14.61 |
| Forward PE | 11.89 |
| Dividend | $1.98 (4.91%) |
| Ex-Dividend Date | Aug 18, 2022 |
| Volume | 2,889,524 |
| Open | 40.56 |
| Previous Close | 40.57 |
| Day's Range | 40.18 - 40.66 |
| 52-Week Range | 32.96 - 47.89 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 53.20 (+32.0%) |
| Earnings Date | Jul 27, 2022 |
About GSK
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, ... [Read more...]
Financial Performance
In 2021, GSK plc's revenue was 34.11 billion, an increase of 0.04% compared to the previous year's 34.10 billion. Earnings were 4.39 billion, a decrease of -23.73%.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to 34 analysts, the average rating for GSK stock is "Buy." The 12-month stock price forecast is 53.2, which is an increase of 31.98% from the latest price.
News
ADDING MULTIMEDIA GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in comm...
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leade...
GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leade...
GSK or Haleon: Which Is the Real Beneficiary of This Spinoff?
GSK PLC ( GSK , Financial) completed the long-awaited spinoff of its consumer health care business Haleon ( HLN , Financial) on July 18. Shareholders received one Haleon share for each GSK share owned.
Could GSK's Haleon Spinoff Backfire?
GSK PLC ( GSK , Financial) completed the long-awaited spinoff of its consumer health care business Haleon ( HLN , Financial) on July 18. Shareholders received one Haleon share for each GSK share owned.
GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
LONDON--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active l...
Drug Behemoth GSK Delivers Strong Beat And Raise, But Shares Fell
Early Wednesday, GSK stock dipped slightly despite beating second-quarter expectations and raising its full-year guidance. The post Drug Behemoth GSK Delivers Strong Beat And Raise, But Shares Fell appe...
GSK lifts full-year forecast, days after consumer health spinoff
GSK on Wednesday lifted its full-year forecast, boosted by reinvigorated demand for its blockbuster Shingrix vaccine, days after overhauling the business with the spinoff of its consumer health unit.
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
Why GlaxoSmithKline Stock Jumped 25% on Thursday
Investors may be warming to the company's spin-off of its consumer healthcare division.
3 Biotech Stocks to Buy on the Dip
Biotech stocks have rebounded lately and are poised to keep surging, so it's a good time to buy biotech stocks on the dip. The post 3 Biotech Stocks to Buy on the Dip appeared first on InvestorPlace.
We expected volatility in the early days of trading, says Haleon CEO Brian McNamara
Brian McNamara, Haleon CEO, joins 'Squawk Box' to discuss the company first few days as a publicly traded company.
GSK Completes Demerger of Consumer Healthcare Business
Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.
Haleon launches with purpose to deliver better everyday health with humanity
Maker of Sensodyne, Advil, and TUMS becomes one of the world's leading independent consumer health companies Demerger from GSK plc (GSK) now complete WARREN, N.J. , July 18, 2022 /PRNewswire/ -- Today, ...
GSK spinoff starts trading at LSE – what you need to know
Monday, July 18, is set up to be a big day for GlaxoSmithKline (NYSE: GSK) and the London Stock Exchange.
GSK spinoff Haleon starts trading in largest European listing in a decade
Europe's biggest listing in a decade, Haleon, started trading on the London Stock Exchange on Monday. Haleon in the consumer-health business spinoff of GSK GSK, -19.57%.
After bruising year, GSK approaches consumer split in better health
Things are looking up for GSK and its chief Emma Walmsley as the British drugs giant prepares to spin off its consumer health business on Monday in London's biggest listing in a decade and the company's...
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
PHILADELPHIA--(BUSINESS WIRE)-- #Flu--GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
How Its New Vaccine Could Propel GSK's Growth
GSK leads the race to deliver a vaccine for an untreated infectious disease.
How to Earn $10,000 a Year in Passive Retirement Income
You'll either need a decent chunk of change or some patience.
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
PHILADELPHIA--(BUSINESS WIRE)-- #Diversity--GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community
Sanofi, GSK say their next-generation COVID-19 booster has 72% efficacy against omicron
Sanofi SNY, +0.38% SAN, +3.70% and GlaxoSmithKline GSK, +1.86% said Friday that their experimental bivalent COVID-19 booster had a 72% efficacy rate against omicron, and they now plan to submit the data...
Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron
Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is the firs...